Editas Medicine, Inc. — Director's Dealing 2017

Dec 19, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2017-12-15

Reporting Person: Hack Andrew A. F. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-15	Common Stock	M	5000	$3.23	Acquired	5000	Direct
2017-12-15	Common Stock	S	5000	$24.3092	Disposed	0	Direct
2017-12-18	Common Stock	M	5000	$3.23	Acquired	5000	Direct
2017-12-18	Common Stock	S	5000	$24.6818	Disposed	0	Direct
2017-12-19	Common Stock	M	4649	$3.23	Acquired	4649	Direct
2017-12-19	Common Stock	S	4649	$25.0614	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-15	Stock Option (right to buy)	$3.23	M	5000	Disposed	2025-07-13	Common Stock (5000)	Direct
2017-12-18	Stock Option (right to buy)	$3.23	M	5000	Disposed	2025-07-13	Common Stock (5000)	Direct
2017-12-19	Stock Option (right to buy)	$3.23	M	4649	Disposed	2025-07-13	Common Stock (4649)	Direct

Footnotes

F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.

F2: This transaction was executed in multiple trades at prices ranging from $24.20 to $24.49. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $24.50 to $25.24. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $24.75 to $25.73. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected

F5: This option was granted on July 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019.